Obesity is a common etiology of diabetes mellitus and other diseases. Certain adipocytokines are considered beneficial due to their ability to enhance insulin sensitivity, while others, considered detrimental, enhance insulin resistance.
The beneficial adipocytokine adiponectin displays both anti-diabetic and anti-arteriosclerotic effects. Two distinct adiponectin receptors have been identified. Both AdipoR1 and AdipoR2 are seven-pass transmembrane receptors but are structurally, topologically, and functionally distinct from G-protein coupled receptors (GPCR) (Ref.1). AdipoR1 is most abundant in muscle whereas AdipoR2 is most abundant in liver. Both receptors promote fatty acid oxidation and glucose uptake by AMP-activated protein kinase and PPARalpha
PPAR agonists are reported to increase expression of activated adiponectin. PPARα agonists also increase expression of adiponectin receptors (Ref.2). Such findings have focused attention on the role of AdipoR1 in PPAR agonist development.
1 Yamauchi T. et al.: Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature. 2003 Jun 12;423(6941):762-9.
2 Tsuchida A. et al. : Insulin/Foxo1 pathway regulates expression levels of adiponectin receptors and adiponectin sensitivity. J Biol Chem. 2004 Jul 16;279(29):30817-22.
Lane 1: Denaturing recombinant Adiponectin.
Lane 2: Non-denaturing recombinant Adiponectin.
The protein bands were visualized with ECL detection system
Anti AdipoR 1
Anti PPAR GAMMA